Intravenous immunoglobulin therapy combined with Vitamins E and C for Kawasaki Disease

Not Applicable

• Conditions: Kawasaki disease

• Registration Number: JPRN-UMIN000037134
• Lead Sponsor: Fukuoka Children's Hospital Kawasaki disease center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-24
• Study Completion: 2021-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Cases after the 9th disease day 2. Cases who is taking vitamins at the onset of Kawasaki disease 3. Cases who have coronaly artery lesion at entry 4. Recurrent or relapsed cases of Kawasaki disease 5. Cases whose cause of fever is other than Kawasaki disease 6. Cases who received immunoglobulin within 90 days before entry 7. Cases with serious underlying diseases 8. Cases taking immunosuppressive drugs such as steroids 9. Cases with other diseases that require oral administration of anticoagulants and antiplatelets 10. Cases with allergies to vitamins 11. Other cases judged by the investigator as inappropriate

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The time from the start of treatment to fever reduction

Secondary Outcome Measures

Name	Time	Method
Hospitalization period, CRP after treatment, Ratio of refractory cases, Ratio of relapsed cases, Complication rate of coronary artery lesion(during hospitalization, 1 month after onset), change of Z-score, change of LOX-1 ligand(before treatment, after fever reduction, 1 month after onset)